問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
劉奕廷
下載
2025-02-03 - 2029-12-23
Condition/Disease
● Overall survival (OS) is defined as the time elapsed from random assignment until death from any cause.
Test Drug
TPST-1120
Participate Sites6Sites
Recruiting6Sites
2025-08-01 - 2030-12-31
Neoplasms
錠劑
Participate Sites2Sites
Recruiting2Sites
2025-03-01 - 2030-02-01
HER2-positive gastric cancer or gastroesophageal junction cancer
Trastuzumab Deruxtecan (T-DXd)
Participate Sites5Sites
Recruiting5Sites
2025-10-01 - 2029-12-31
Squamous Cell Carcinoma of Head and Neck
注射劑 皮下注射劑 注射劑 注射劑 注射劑
Participate Sites7Sites
Recruiting7Sites
2025-11-14 - 2029-06-30
NSCLC Adenocarcinoma
錠劑 膠囊劑 錠劑
Participate Sites4Sites
Recruiting4Sites
2023-09-01 - 2033-12-31
Terminated2Sites
2023-09-01 - 2027-12-31
2020-09-01 - 2026-12-31
2020-09-01 - 2027-06-30
Not yet recruiting1Sites
2021-04-01 - 2033-02-28
全部